{
  "trial_id": "NCT01828294",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "AChR Ab positive myasthenia gravis",
      "label": "met",
      "evidence": "positive anti-AChR antibody test"
    },
    {
      "criterion": "Age 18-80 years",
      "label": "met",
      "evidence": "16-year-old girl"
    },
    {
      "criterion": "MGFA Classification II-IV",
      "label": "met",
      "evidence": "class IIa"
    },
    {
      "criterion": "Receiving > or equal 30mg of Prednisone per day",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "No new MG-specific treatments in prior 3 months",
      "label": "met",
      "evidence": "on acetylcholinesterase inhibitor treatment combined with immunosuppressants"
    },
    {
      "criterion": "Willingness to participate in study protocol",
      "label": "met",
      "evidence": ""
    },
    {
      "criterion": "QMG > 10",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Treatment with any immunomodulator > than or equal to 3 months prior to trial initiation",
      "label": "met",
      "evidence": "on acetylcholinesterase inhibitor treatment combined with immunosuppressants"
    },
    {
      "criterion": "Age 18-80 years",
      "label": "met",
      "evidence": "16-year-old girl"
    },
    {
      "criterion": "MGFA Classification II-IV",
      "label": "met",
      "evidence": "class IIa"
    },
    {
      "criterion": "Receiving > or equal 30mg of Prednisone per day",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "No new MG-specific treatments in prior 3 months",
      "label": "met",
      "evidence": "on acetylcholinesterase inhibitor treatment combined with immunosuppressants"
    }
  ],
  "exclusion": [
    {
      "criterion": "IgA deficiency",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Previous thromboembolic events, including deep vein thrombosis, stroke and myocardial infarction",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "MGFA Class I, IV (if patient requires hospitalization) or V",
      "label": "unknown",
      "evidence": "class IIa"
    },
    {
      "criterion": "History of thymoma",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Thymectomy in previous year or planning to undergo thymectomy in next six months",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Pregnancy or lactation; unwillingness to avoid pregnancy",
      "label": "met",
      "evidence": "Beta hcg: negative for pregnancy"
    },
    {
      "criterion": "Serious concurrent medical, neurological or psychiatric condition that would interfere with IGSC administration or subsequent clinical assessments",
      "label": "unknown",
      "evidence": ""
    },
    {
      "criterion": "Unwillingness or incapacity to participate, agree to necessary follow-up visits, or give written and informed consent",
      "label": "met",
      "evidence": ""
    }
  ],
  "notes": "16-year-old girl recently diagnosed with myasthenia gravis, class IIa. She complains of diplopia and weakness affecting in her upper extremities.",
  "_meta": {
    "topic_id": "72",
    "trial_id": "NCT01828294",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}